关键词: 胰腺癌, 新辅助治疗, 可切除性评估

Abstract: Progress and controversy of resectability assessment for pancreatic cancer after neoadjuvant therapy    ZHAO Zi-xuan*，XIAO Jian-chun，ZHANG Tai-ping，et al. *Department of General Surgery，Peking Union Medical College Hospital，Chinese Academy of Medical Sciences，Beijing 100730，China
Corresponding author：ZHAO Yu-pei，E-mail: zhao8028@263.net
Abstract    Pancreatic cancer has an insidious onset，rapid progress and a very poor prognosis. Surgical resection is the only possible way to cure pancreatic cancer，but most patients are not eligible for radical resections at diagnosis. Neoadjuvant therapy has been increasingly important in the comprehensive treatment of pancreatic cancer，which can reduce the tumor stage and increase the R0 resection rate for some patients. At present，the resectability assessment of pancreatic cancer after neoadjuvant therapy mainly rely on the patient's imaging performances，combined with clinical symptoms，the level of tumour markers and systemic conditions. As is recommended by the NCCN guideline，patients with reduced or stable levels of CA19-9 and improved clinical symptoms whose imaging doesn’t suggest significant progression or distant metastases can be considered for surgical resection. However，due to difficulties in detecting small metastases and evaluating pathological changes as well as the limitations in current examinational and surgical methods，there are still arguments about the existing assessment standards. It is still hard to accurately and objectively evaluate the surgical indications in clinical work for pancreatic cancer patients after neoadjuvant therapy.

Key words: pancreatic cancer, neoadjuvant therapy, resectability assessment